methyl 4-(6-chloro-3-nitropyridin-2-yloxy)benzoate | 1402088-11-2

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: methyl 4-(6-chloro-3-nitropyridin-2-yloxy)benzoate
• 英文别名: methyl 4-(6-chloro-3-nitropyridin-2-yl)oxybenzoate
• CAS: 1402088-11-2
• 化学式: C₁₃H₉ClN₂O₅
• 分子量: 308.678
• InChiKey: ZYPIUZXAUNRMLD-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.4
• 重原子数：
  21
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.08
• 拓扑面积：
  94.2
• 氢给体数：
  0
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  methyl 4-(6-chloro-3-nitropyridin-2-yloxy)benzoate 在 氢气 、 potassium carbonate 作用下， 以 甲醇 、 水 、 N,N-二甲基甲酰胺 为溶剂， 反应 3.5h， 生成 methyl 4-(3-amino-6-(4-methylpiperazin-1-yl)pyridin-2-yloxy)benzoate
  参考文献：
  名称：

  Furo-3-carboxamide derivatives and methods of use

  摘要：

  式(I)的化合物及其药学上可接受的盐、酯、酰胺或放射标记形式，在该式中R1、Z1、Z2和n如规范中所定义，可用于治疗由Tropomysin受体激酶(Trk)预防或改善的症状或疾病。公开了制备这些化合物的方法。还公开了式(I)化合物的药物组合物，以及使用这些化合物和组合物的方法。

  公开号：

  US09777020B2
• 作为产物：
  描述：

  2,6-二氯-3-硝基吡啶 、 对羟基苯甲酸甲酯 在 sodium hydride 作用下， 以 四氢呋喃 、 5,5-dimethyl-1,3-cyclohexadiene 为溶剂， 反应 16.42h， 生成 methyl 4-(6-chloro-3-nitropyridin-2-yloxy)benzoate
  参考文献：
  名称：

  Furo-3-carboxamide derivatives and methods of use

  摘要：

  式(I)的化合物及其药学上可接受的盐、酯、酰胺或放射标记形式，在该式中R1、Z1、Z2和n如规范中所定义，可用于治疗由Tropomysin受体激酶(Trk)预防或改善的症状或疾病。公开了制备这些化合物的方法。还公开了式(I)化合物的药物组合物，以及使用这些化合物和组合物的方法。

  公开号：

  US09777020B2

文献信息

• FURO-3-CARBOXAMIDE DERIVATIVES AND METHODS OF USE
  申请人：AbbVie Inc.

  公开号：US20150210720A1

  公开（公告）日：2015-07-30

  Compounds of formula (I) and pharmaceutically acceptable salts, esters, amides, or radiolabelled forms thereof, wherein R 1 , Z 1 , Z 2 , and n are as defined in the specification, are useful in treating conditions or disorders prevented by or ameliorated by Tropomysin receptor kinases (Trk). Methods for making the compounds are disclosed. Also disclosed are pharmaceutical compositions of compounds of formula (I), and methods for using such compounds and compositions.

  式(I)化合物的药物可接受的盐、酯、酰胺或放射性标记形式，其中R1、Z1、Z2和n如说明书中所定义，可用于治疗通过或通过原肌球蛋白受体激酶(Trk)预防或缓解的病症或障碍。制备这些化合物的方法已被公开。还公开了式(I)化合物的药物组合物，以及使用这些化合物和组合物的方法。
• Design and synthesis of diarylamines and diarylethers as cytotoxic antitumor agents
  作者：Xiao-Feng Wang、Xing-Tao Tian、Emika Ohkoshi、Bingjie Qin、Yi-Nan Liu、Pei-Chi Wu、Mann-Jen Hour、Hsin-Yi Hung、Keduo Qian、Rong Huang、Kenneth F. Bastow、William P. Janzen、Jian Jin、Susan L. Morris-Natschke、Kuo-Hsiung Lee、Lan Xie

  DOI：10.1016/j.bmcl.2012.08.014

  日期：2012.10

  Based on a shared structural core of diarylamine in several known anticancer drugs as well as a new cytotoxic hit 6-chloro-2-(4-cyanophenyl)amino-3-nitropyridine (7), 30 diarylamines and diarylethers were designed, synthesized, and evaluated for cytotoxic activity against A549, KB, KB-vin, and DU145 human tumor cell lines (HTCL). Four new leads 11e, 12, 13a, and 13b were discovered with GI(50) values ranging from 0.33 to 3.45 mu M. Preliminary SAR results revealed that a diarylamine or diarylether could serve as an active structural core, meta-chloro and ortho-nitro groups on the A-ring (either pyridine or phenyl ring) were necessary and crucial for cytotoxic activity, and the para-substituents on the other phenyl ring (B-ring) were related to inhibitory selectivity for different tumor cells. In an investigation of potential biological targets of the new leads, high thoughput kinase screening discovered that new leads 11e, 12 and 13b especially inhibit Mer tyrosine kinase, a proto-oncogene associated with munerous tumor types, with IC50 values of 2.2-3.0 mu M. Therefore, these findings provide a good starting point to optimize a new class of compounds as potential anticancer agents, particularly targeting Mer tyrosine kinase. (C) 2012 Elsevier Ltd. All rights reserved.
• US9777020B2
  申请人：——

  公开号：US9777020B2

  公开（公告）日：2017-10-03
• [EN] FURO-3-CARBOXAMIDE DERIVATIVES AND METHODS OF USE<br/>[FR] DÉRIVÉS FURO-3-CARBOXAMIDE ET MÉTHODES D'UTILISATION
  申请人：ABBVIE INC

  公开号：WO2015112754A1

  公开（公告）日：2015-07-30

  Compounds of formula (I) and pharmaceutically acceptable salts, esters, amides, or radiolabelled forms thereof, wherein R1, Z1, Z2, and n are as defined in the specification, are useful in treating conditions or disorders prevented by or ameliorated by Tropomysin receptor kinases (Trk). Methods for making the compounds are disclosed. Also disclosed are pharmaceutical compositions of compounds of formula (I), and methods for using such compounds and compositions.